Nomic Bio, a leader in protein profiling, has successfully completed a $42 million Series B funding round that was oversubscribed. This significant capital infusion will propel the company’s efforts to enhance its cutting-edge protein profiling platform and expand its commercial operations, catering to the rising demand in the proteomics field.
Led by a prominent U.S.-based life sciences investor, the funding round included contributions from established and new investors such as Amplitude Ventures, AVANT BIO, Lux Capital, Real Ventures, and SR One. With this latest financing, Nomic has raised over $60 million in total.
“Proteomics has the potential to drive the next generation of therapeutics and diagnostics,” noted Byron Hewett, former CEO of Somalogic and current board member at Nomic. “Scalability and data fidelity are critical for proteomics technologies. But for broad adoption and utility, the technology must also be broadly accessible and versatile. We believe Nomic’s nELISA™ platform achieves exactly that.”
The company is revolutionizing the proteomics landscape, supporting over 75 companies—including major pharmaceutical firms, innovative biotechs, and esteemed research institutions—who have collectively profiled more than 400,000 samples. In response to increasing demand, Nomic has established industrial-scale facilities powered by its innovative nELISA platform, providing clients with a streamlined protein profiling service characterized by high throughput and rapid turnaround times.
Milad Dagher, CEO and Co-founder of Nomic, stated, “Nomic was founded to help scientific teams succeed in their mission to extend health spans. Witnessing our technology embraced by innovative R&D teams and advancing critical drug discovery efforts is exhilarating. With this funding, we aim to broaden our biological footprint and unlock new applications in collaboration with our distinguished investors.”
Nomic’s nELISA technology exemplifies a paradigm shift in protein profiling, enabling extensive multiplexing and cost-efficient quantification. The company is committed to expanding its offerings across the proteome, promising new avenues for applications in various disease areas.
Editorial Opinion
Nomic Bio stands at the forefront of the rapidly evolving biotechnology landscape, especially within the proteomics sector. With a robust funding round and a clear vision for growth, Nomic is poised to make significant strides in drug discovery and diagnostics. The potential for scalability and the company’s commitment to accessibility make it a key player in transforming the future of therapeutics.
As the demand for innovative biotechnological solutions continues to rise, Nomic’s expansion efforts and strategic partnerships position it favorably within a competitive market. By focusing on advancing its state-of-the-art protein profiling platform, Nomic is not just contributing to scientific advancement; it is laying the groundwork for groundbreaking developments that could enhance patient outcomes worldwide. Nomic.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
